Alejandro de la Cruz, MD
Internal Medicine · Miami, FLNPI 1245521186
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 158 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations.
Across 158 payments — averaging $24.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$866
- GSK$809
- Amarin Pharma, Inc.$539
- Johnson & Johnson$287
- Sanofi-aventis U.S. LLC$178
- Bayer$167
- plus $965 from 14 others
Across 211 payments — averaging $29,486 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bavarian Nordic A/s$2.9M
- GSK$1.4M
- Pfizer$1.1M
- Hikma Pharmaceuticals USA$349K
- Ionis Pharmaceuticals, Inc.$247K
- Cipla USA Inc.$175K
- plus $82K from 5 others
What the payments were for
- Food & beverage$3,811100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 35 | $866 |
| GSK | 35 | $809 |
| Amarin Pharma, Inc. | 15 | $539 |
| Johnson & Johnson | 15 | $287 |
| Sanofi-aventis U.S. LLC | 4 | $178 |
| Bayer | 7 | $167 |
| Abbott | 8 | $151 |
| Pfizer | 6 | $138 |
| Exact Sciences | 4 | $116 |
| Novo Nordisk | 5 | $102 |
| E.r. Squibb & Sons, L.L.C. | 4 | $87 |
| Amgen | 4 | $79 |
| Phathom Pharmaceuticals, Inc. | 3 | $66 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $52 |
| Sunovion Pharmaceuticals Inc. | 3 | $48 |
| Boehringer Ingelheim | 2 | $47 |
| Kowa Pharmaceuticals America, Inc. | 2 | $35 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $14 |
| Metacel Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$259
- TOUJEO$125
- SOLIQUA 100/33$125
- BREZTRI$125
How this compares
$3,811 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 81 | $102,543 |
| OzempicSemaglutide | 63 | $79,696 |
| FarxigaDapagliflozin Propanediol | 76 | $65,535 |
| JanuviaSitagliptin Phosphate | 74 | $63,945 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 72 | $61,828 |
| JardianceEmpagliflozin | 34 | $37,216 |
| XareltoRivaroxaban | 31 | $34,804 |
| MounjaroTirzepatide | 20 | $27,558 |
| EntrestoSacubitril/Valsartan | 18 | $19,417 |
| LinzessLinaclotide | 31 | $17,421 |
| Tadalafil | 103 | $16,790 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $14,774 |
| BrilintaTicagrelor | 13 | $10,841 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $8,587 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 26 | $8,347 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $138 | $102,54381 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $866 | $99,737131 claims |
| Novo NordiskOzempic | $102 | $79,69663 claims |
| GSKTrelegy Ellipta | $809 | $61,82872 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $47 | $43,95448 claims |
| Johnson & JohnsonXarelto | $287 | $34,80431 claims |
| Lilly USA, LLCMounjaro | $14 | $27,55820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Miami
- Haytham ElgammalMiami$2.2M
- Richard AguilarMiami$239K
- Maria Delgado LelievreMiami$80K
- Marlow HernandezMiami$58K
- Steven CohnMiami$47K
- Joseph PiperatoMiami$45K
- Simon AbelsonMiami$44K
- Joel Brooks TamayoMiami$42K
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.